Skip to main content
Faes Farma S.A. logo

Faes Farma S.A. — Investor Relations & Filings

Ticker · FAE ISIN · ES0134950F36 LEI · 959800FXZQY7U3P1G969 MC Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2026-05-06 AGM Information
Country ES Spain
Listing MC FAE

About Faes Farma S.A.

https://faesfarma.com/en/

Faes Farma S.A. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products, healthcare solutions, and animal nutrition products. The company's pharmaceutical division develops treatments for conditions in therapeutic areas including allergy, gastroenterology, and immunology, with key proprietary molecules such as Bilastine, a leading antihistamine, and Calcifediol for Vitamin D deficiency. The animal nutrition business provides nutritional solutions and supplements for sustainable animal production. A core focus of the company is its investment in R&D to develop novel molecules and health solutions for its global markets.

Recent filings

Filing Released Lang Actions
Convocatoria de la Junta General de Accionistas de 2026
AGM Information Classification · 100% confidence The document is a detailed notice of a shareholders' meeting (Junta General de Accionistas) for Faes Farma, S.A., including the agenda items such as approval of annual accounts, management reports, election of directors, remuneration policies, and auditor appointment. It is a formal convocation (call) for the Annual General Meeting (AGM) scheduled for June 2026. The text includes procedural details about voting, representation, and documentation availability but does not contain the actual annual report or financial statements themselves. The document is not a report but a meeting notice and agenda, which fits the definition of AGM Information (AGM-R). The length and detail confirm it is not a brief announcement but a full AGM convocation document.
2026-05-06 Spanish
Convocatoria de la Junta General de Accionistas de 2026
AGM Information Classification · 95% confidence The document is a detailed notice of a shareholders' meeting (Junta General de Accionistas) for Faes Farma, S.A., including the agenda items such as approval of annual accounts, re-election of directors, remuneration reports, appointment of auditors, and voting procedures. It is a formal convocation or invitation to the Annual General Meeting (AGM) rather than the actual meeting materials or minutes. The document does not contain financial statements or detailed financial analysis but rather the announcement and procedural information for the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length and detail support this classification with high confidence.
2026-05-06 Spanish
Informe de negocio del primer trimestre de 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'INFORME Q1 2026' and contains detailed financial data and analysis for the first quarter of 2026, including revenue, EBITDA, net income, and segment performance. It includes comprehensive financial tables, business evolution, and management commentary on results and outlook. The length is over 14,000 characters, indicating a substantive report rather than a brief announcement. The content focuses on quarterly financial results and business performance, which aligns with an Interim / Quarterly Report. There is no indication that this is an annual report, audit report, or earnings release (which would be shorter and more summary). It is not a presentation or a regulatory filing. Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2026-04-30 Spanish
Faes Farma anuncia la celebración de un webcast para presentar los resultados del primer trimestre de 2026
Regulatory Filings Classification · 75% confidence The document is a brief notice filed with the Spanish CNMV under “Otra Información Relevante” announcing a webcast date/time for Q1 2026 results. It does not contain the actual earnings figures or Q&A transcript, nor is it a full financial report, dividend notice, management change, or any other specific category. It is a general regulatory announcement of an upcoming event, so it falls into the fallback Regulatory Filings category (RNS).
2026-04-22 Spanish
Informe de negocio 2025
Investor Presentation Classification · 98% confidence The document is a comprehensive 'Informe 2025' (2025 Report) for Faes Farma. It contains detailed financial results, business unit performance, sustainability strategies, and management commentary on the fiscal year 2025. Given its length (over 25,000 characters), detailed financial tables, and strategic outlook, it functions as an annual performance report. While it is not a formal 10-K (which is a specific US regulatory filing), it serves the same purpose as an Annual Report for a non-US entity, providing a full review of the company's yearly activity and financial performance.
2026-02-26 Spanish
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2025
Remuneration Information Classification · 100% confidence The document is a detailed report on the remuneration policy for directors of Faes Farma, S.A. It covers the procedures for determining compensation, the mix of fixed and variable pay, long-term incentive structures, and clawback/malus clauses. This content is characteristic of a Remuneration Report, which is a standard component of proxy statements or standalone governance filings. Given the specific focus on executive and director compensation policies, it falls under the 'DEF 14A' category.
2026-02-26 Spanish

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.